Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Aug 8;13(3):119.
doi: 10.3390/medsci13030119.

Adherence, Persistence, and Blood Pressure Control in Hypertensive Patients: A Cross-Sectional Study in Mureș County, Romania

Affiliations

Adherence, Persistence, and Blood Pressure Control in Hypertensive Patients: A Cross-Sectional Study in Mureș County, Romania

Radu Tatar et al. Med Sci (Basel). .

Abstract

Background: Nonadherence to antihypertensive therapy affects nearly half of treated patients worldwide, and persistence often falls below 60% within the first year, contributing substantially to uncontrolled blood pressure and cardiovascular morbidity. Adherence and persistence to antihypertensive therapy among primary care patients in Mureș County, Romania, were assessed using validated measures, and modifiable risk factors for targeted interventions were identified. Methods: A cross-sectional study of 399 hypertensive adults (≥18 years) receiving treatment for ≥1 year across primary care clinics in Mureș County, Romania, was performed. Adherence was evaluated using the Romanian-validated Hill-Bone Compliance to High Blood Pressure Therapy Scale (HBCTS) and confirmed by mean arterial pressure (MAP) < 100 mmHg. Receiver operating characteristic (ROC) curve analysis was employed to determine the optimal HBCTS cutoff, and multivariate logistic regression was used to identify independent predictors of adherence. Persistence was assessed via healthcare-engagement metrics over a 360-day observation period. Results: Effective blood pressure control (MAP < 100 mmHg) was achieved by 45.9% of participants. The HBCTS demonstrated good reliability (McDonald's ω = 0.82). ROC analysis established 51 points as an optimal threshold (sensitivity = 88.0%, specificity = 38.9%). Male gender (OR = 0.47, 95% CI: 0.29-0.75, p = 0.002) and younger age (OR = 1.04 per year, 95% CI: 1.01-1.06, p = 0.001) independently predicted poor adherence. Treatment coverage days showed the strongest correlation with blood pressure control (r = -0.50, p < 0.001). Among participants, 67.7% demonstrated persistence, achieving significantly better blood pressure control than non-persistent patients. Conclusions: The validated HBCTS (≥51 points) provides an efficient screening tool for Romanian primary care settings. Treatment coverage days emerged as the strongest modifiable predictor of blood pressure control (r = -0.50), highlighting medication availability as a key intervention target. Targeted approaches for male and younger patients, combined with systematic medication continuity monitoring, represent evidence-based strategies for reducing cardiovascular morbidity in this population.

Keywords: Hill–Bone Compliance to High Blood Pressure Therapy Scale (HBCTS); Romania; hypertension; medication adherence; primary care.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflicts of interest.

Figures

Figure 1
Figure 1
Study participant flow diagram. Abbreviations: n, number.
Figure 2
Figure 2
Receiver operating characteristic curve for HBCTS performance in identifying adherence. The solid line represents the model’s performance, while the dotted diagonal line indicates the line of no discrimination.
Figure 3
Figure 3
Impact of treatment continuity on blood pressure control. Abbreviations: MAP, mean arterial pressure; x, total days of coverage.
Figure 4
Figure 4
Association between medication adherence score and blood pressure control. Abbreviations: HBCTS, Hill–Bone compliance to high blood pressure therapy; MAP, mean arterial pressure; x, total points/patient.

References

    1. Mills K.T., Stefanescu A., He J. The global epidemiology of hypertension. Nat. Rev. Nephrol. 2020;16:223–237. doi: 10.1038/s41581-019-0244-2. - DOI - PMC - PubMed
    1. Kario K., Okura A., Hoshide S., Mogi M. The WHO Global report 2023 on hypertension warning the emerging hypertension burden in globe and its treatment strategy. Hypertens. Res. 2024;47:1099–1102. doi: 10.1038/s41440-024-01622-w. - DOI - PubMed
    1. Hamrahian S.M., Maarouf O.H., Fülöp T. A critical review of medication adherence in hypertension: Barriers and facilitators clinicians should consider. Patient Prefer. Adherence. 2022;16:2749–2757. doi: 10.2147/PPA.S368784. - DOI - PMC - PubMed
    1. Lee H., Yano Y., Cho S.M.J., Wozniak G., Jeon J., Choi H., Mehta A., Michos E.D., Blumenthal R.S., Chang A.R. Adherence to antihypertensive medication and incident cardiovascular events in young adults with hypertension. Hypertension. 2021;77:1341–1349. doi: 10.1161/HYPERTENSIONAHA.120.16784. - DOI - PubMed
    1. Menditto E., Cahir C., Malo S., Aguilar-Palacio I., Almada M., Costa E., Giardini A., Kanavos P., Ferrara P., Pinget C., et al. Persistence as a robust indicator of medication adherence-related quality and performance. Int. J. Environ. Res. Public Health. 2021;18:4872. doi: 10.3390/ijerph18094872. - DOI - PMC - PubMed

Substances

LinkOut - more resources